Ribonucleotide reductase activity and growth of glutathione-depleted mouse leukemia L1210 cells in vitro

Cancer Lett. 1988 Jun 30;40(3):257-64. doi: 10.1016/0304-3835(88)90084-5.

Abstract

L1210 cells treated with L-buthionine-(S/R)-sulfoximine (BSO) had glutathione (GSH) and non-protein thiol levels only 15% that of control. These GSH-depleted cells grew as well as the control L1210 cells and there was no decrease in ribonucleotide reductase activity in situ as measured by the conversion of [14C]cytidine to deoxytidine nucleotides and incorporation into DNA. Further, when these BSO-stressed cells were treated with hydroxyurea or IMPY, there was no potentiation of the inhibition caused by hydroxyurea or IMPY alone. These data indicate that the glutathione/glutaredoxin system of ribonucleotide reductase is not the sole carrier of reducing equivalents from NADPH for the reduction of the 2'-position of the corresponding ribonucleoside 5'-diphosphate; and that glutathione is not critical in regenerating the tyrosyl free-radical on the M2 subunit which is destroyed by the hydroxyurea or 2,3-dihydro-1H-pyrazolo-[2,3-alpha]imidazole (IMPY) treatment.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Buthionine Sulfoximine
  • Cell Division
  • Cells, Cultured
  • Cytidine
  • Glutathione / deficiency*
  • Hydroxyurea / pharmacology
  • Leukemia L1210 / enzymology*
  • Leukemia L1210 / pathology
  • Methionine Sulfoximine / analogs & derivatives
  • Methionine Sulfoximine / pharmacology
  • Mice
  • Pyrazoles / pharmacology
  • Ribonucleotide Reductases / metabolism*

Substances

  • Pyrazoles
  • Methionine Sulfoximine
  • Buthionine Sulfoximine
  • Cytidine
  • Ribonucleotide Reductases
  • Glutathione
  • 2,3-dihydro-1H-imidazo(1,2-b)pyrazole
  • Hydroxyurea